- Home
- TRIB vs BRNS Comparison
TRIB vs BRNS Comparison
Compare TRIB & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- BRNS
- Stock Information
- Founded
- TRIB 1992
- BRNS 2016
- Country
- TRIB Ireland
- BRNS United Kingdom
- Employees
- TRIB 380
- BRNS N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- BRNS Health Care
- Exchange
- TRIB Nasdaq
- BRNS Nasdaq
- Market Cap
- TRIB 10.7M
- BRNS 28.2M
- IPO Year
- TRIB N/A
- BRNS 2021
- Fundamental
- Price
- TRIB $0.71
- BRNS $0.82
- Analyst Decision
- TRIB
- BRNS Strong Buy
- Analyst Count
- TRIB 0
- BRNS 2
- Target Price
- TRIB N/A
- BRNS $3.00
- AVG Volume (30 Days)
- TRIB 40.9K
- BRNS 25.9K
- Earning Date
- TRIB 05-22-2025
- BRNS 05-12-2025
- Dividend Yield
- TRIB N/A
- BRNS N/A
- EPS Growth
- TRIB N/A
- BRNS N/A
- EPS
- TRIB N/A
- BRNS N/A
- Revenue
- TRIB $59,126,000.00
- BRNS $14,969,000.00
- Revenue This Year
- TRIB $11.63
- BRNS N/A
- Revenue Next Year
- TRIB $10.13
- BRNS N/A
- P/E Ratio
- TRIB N/A
- BRNS N/A
- Revenue Growth
- TRIB N/A
- BRNS 1766.46
- 52 Week Low
- TRIB $0.48
- BRNS $0.64
- 52 Week High
- TRIB $3.55
- BRNS $2.60
- Technical
- Relative Strength Index (RSI)
- TRIB 62.34
- BRNS 51.00
- Support Level
- TRIB $0.51
- BRNS $0.68
- Resistance Level
- TRIB $0.57
- BRNS $0.97
- Average True Range (ATR)
- TRIB 0.06
- BRNS 0.08
- MACD
- TRIB 0.02
- BRNS 0.02
- Stochastic Oscillator
- TRIB 97.02
- BRNS 54.79
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.